DHX33

Across TCGA pan-cancer cohorts, DHX33 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated DHX33 data layer compared with 27 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher DHX33 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated DHX33 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where DHX33 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.210	0.509	.002	57	view →
CCRCC	OS	Median	All	1.000	0.900	.035	8	view →
LUAD	DFS	Median	II,III,IV	0.958	0.764	.036	5	view →
LSCC	DFS	Quartile	II,III,IV	0.790	0.457	.033	2	view →
HNSC	DFS	Median	III,IV	0.915	1.000	.037	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

DHX33–PDAC (DFS)

Open the PDAC breakdown →